Alexion adds fourth indication for C5 inhibitor UltomirisC5 inhibitor Ultomiris in rare autoimmune disorder
2024-03-25
上市批准临床3期临床结果
AstraZeneca’s rare disease arm Alexion scored its fourth approval for Ultomiris in a rare autoimmune disorder after Phase 3 data showed there were zero patients with relapses over 73 weeks.
The FDA approved Ultomiris, the first and only long-acting C5 complement inhibitorC5 complement inhibitor, for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD)aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that affects the central nervous system and can relapse unpredictably. Symptoms can include blindness and neurological problems that can lead to permanent disabilities.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。